Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment. 
Some of the key factors that are driving the adrenocortical carcinoma treatment market are increasing the prevalence of cancer, rising government involvement, increasing funding from various government and non-government organizations. Also, ethical acceptance of adrenocortical carcinoma treatment and high unmet needs in some regions are driving the adrenocortical carcinoma treatment market. However, less awareness and high cost involved in treatment are restraining the global adrenocortical carcinoma treatment market. Also, the introduction of generic drugs in some countries is restraining the growth of adrenocortical carcinoma treatment market. Also, despite the high cost involved in R&D, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for adrenocortical carcinoma treatment market.

Market Analysis and Insights: Global Adrenocortical Carcinoma Treatment Market
The global Adrenocortical Carcinoma Treatment market size is projected to reach US$ 604.5 million by 2027, from US$ 529.2 million in 2020, at a CAGR of 1.5% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenocortical Carcinoma Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenocortical Carcinoma Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenocortical Carcinoma Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenocortical Carcinoma Treatment market.

Global Adrenocortical Carcinoma Treatment Scope and Market Size
Adrenocortical Carcinoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adrenocortical Carcinoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma

Segment by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals